IP Library Granted Patent US 8,729,037
Granted Patent B2
US 8,729,037 · App. 11/982,345 · Granted May 20, 2014

Method and medicament for inhibiting the expression of a given gene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,729,037
App. No.
11/982,345
Granted
May 20, 2014
Kind
B2
Abstract

The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases.

Claims (14)

1. A method for inhibiting expression of a target gene in a mammalian cell in vivo, comprising:

a) introducing into said mammalian cell in vivo an isolated double stranded RNA (dsRNA) comprising two separate non-linked oligoribonucleotide strands, wherein one strand of the dsRNA is complementary to an RNA transcript of at least part of said target mammalian gene and the other strand of the dsRNA is complementary to the first strand, and wherein the dsRNA is 21 base pairs in length; and

b) maintaining the cell produced in step a) for a time sufficient to obtain degradation of an RNA transcript of said target gene, thereby inhibiting the expression of said target gene in said mammalian cell in vivo.

2. The method of claim 1 , wherein at least one of said strands comprises at least one chemically modified nucleotide.

3. The method of claim 2 , wherein said chemically modified nucleotide is a 2′-modified nucleotide.

4. The method of claim 3 , wherein said 2′-modified nucleotide is a 2′-methyl substituted nucleotide.

5. The method of claim 3 , wherein said 2′-modified nucleotide is a 2′-amino substituted nucleotide.

6. The method of claim 2 , wherein said chemically modified nucleotide is a locked nucleotide.

7. The method of claim 1 , wherein the target gene is a mammalian gene or a viral gene.

8. The method of claim 1 , wherein the target gene is selected from the group consisting of an oncogene, a cytokine gene, an Id protein gene, a developmental gene, a PKR gene and a prion gene.

9. The method of claim 1 , wherein the two separate strands hybridize to each other to form the dsRNA.

10. The method of claim 1 , wherein each of the strands is complementary to the other of the strands, and neither is autocomplementary.

11. The method of claim 1 , wherein said dsRNA specifically inhibits the expression of said mammalian target gene using dsRNA-mediated interference.

12. The method of claim 1 , wherein inhibiting the expression of said target gene further comprises inhibiting expression at a concentration of the dsRNA that is lower by one order of magnitude than a concentration required for a corresponding single-stranded oligoribonucleotide to inhibit expression.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: ALNYLAM EUROPE AG
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 023070/0300 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR INFORMATION PREVIOUSLY RECORDED ON REEL 020471 FRAME 0443. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 4, 2008
From: KREUTZER, ROLAND; LIMMER, STEFAN
To: RIBOPHARMA AG
Reel/Frame 020597/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2008
From: KREUTZER, ROLAND; WIRSING, JOHANN N.; LIMMER, STEFAN; HOFFMAN, SONJA
To: RIBOPHARMA AG
Reel/Frame 020471/0443 →
CHANGE OF NAME Recorded Feb 6, 2008
From: RIBOPHARMA AG
To: ALNYLAM EUROPE AG
Reel/Frame 020471/0954 →